Jiang-Jiang Qin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11144473/publications.pdf

Version: 2024-02-01

93	3,530	147726	155592
papers	citations	31 h-index	55 g-index

102	102	102	4340
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structure elucidation of a novel cyclic tripeptide from the marine-derived fungus Aspergillus ochraceopetaliformis DSW-2. Natural Product Research, 2022, 36, 3572-3578.	1.0	4
2	Predicting hERG channel blockers with directed message passing neural networks. RSC Advances, 2022, 12, 3423-3430.	1.7	5
3	Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics. Current Medicinal Chemistry, 2022, 29, 4391-4409.	1.2	3
4	Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Molecular Cancer, 2022, 21, 70.	7.9	15
5	Inhibition of STAT3 Signaling Pathway by Terphenyllin Suppresses Growth and Metastasis of Gastric Cancer. Frontiers in Pharmacology, 2022, 13, 870367.	1.6	8
6	Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review. Annals of Translational Medicine, 2022, 10, 377-377.	0.7	6
7	Characterization of a bioactive meroterpenoid isolated from the marine-derived fungus Talaromyces sp.. Applied Microbiology and Biotechnology, 2022, 106, 2927-2935.	1.7	11
8	Editorial: Biology and Pharmacological Effects of Extracellular Vesicles in Cancer. Frontiers in Molecular Biosciences, 2022, 9, 896561.	1.6	0
9	Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment. Frontiers in Pharmacology, 2022, 13, .	1.6	4
10	Abstract 5293: Rationally developing antibody drug conjugates targeting genomically stable gastric cancer. Cancer Research, 2022, 82, 5293-5293.	0.4	0
11	p-MEK expression predicts prognosis of patients with adenocarcinoma of esophagogastric junction (AEG) and plays a role in anti-AEG efficacy of Huaier. Pharmacological Research, 2021, 165, 105411.	3.1	12
12	PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 692574.	1.6	140
13	Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy. Acta Pharmaceutica Sinica B, 2021, 11, 3966-3982.	5.7	28
14	Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. Journal of Medicinal Chemistry, 2021, 64, 8884-8915.	2.9	78
15	Protein degradation technology: a strategicÂparadigmÂshift in drug discovery. Journal of Hematology and Oncology, 2021, 14, 138.	6.9	45
16	Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Molecular Therapy - Nucleic Acids, 2021, 26, 11-21.	2.3	3
17	Targeting MDM2 for novel molecular therapy: Beyond oncology. Medicinal Research Reviews, 2020, 40, 856-880.	5.0	56
18	The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders. Drug Discovery Today, 2020, 25, 1988-1997.	3.2	11

#	Article	IF	Citations
19	Targeting Î²-Catenin Signaling by Natural Products for Cancer Prevention and Therapy. Frontiers in Pharmacology, 2020, 11, 984.	1.6	25
20	The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?. Frontiers in Cell and Developmental Biology, 2020, 8, 621428.	1.8	40
21	Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges. Frontiers in Oncology, 2020, 10, 1389.	1.3	23
22	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Frontiers in Pharmacology, 2020, 11, 1208.	1.6	23
23	Aspeterreurone A, a Cytotoxic Dihydrobenzofuranâ€“Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18. Journal of Natural Products, 2020, 83, 1998-2003.	1.5	26
24	Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Molecular Cancer, 2020, 19, 96.	7.9	191
25	Cytotoxic Nitrogenated Azaphilones from the Deep-Sea-Derived Fungus Chaetomium globosum MP4-S01-7. Journal of Natural Products, 2020, 83, 1157-1166.	1.5	39
26	Chemical constituents from wetland soil fungus Penicillium oxalicum GY1. FÃ¬toterapÃ¬Ã¢, 2020, 142, 104530.	1.1	6
27	Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resistance Updates, 2020, 49, 100681.	6.5	154
28	Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?. Frontiers in Cell and Developmental Biology, 2020, 8, 233.	1.8	61
29	Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice. Frontiers in Pharmacology, 2020, 11, 457.	1.6	19
30	Synthesis, Characterization, Cellular Uptake, and In Vitro Anticancer Activity of Fullerenol-Doxorubicin Conjugates. Frontiers in Pharmacology, 2020, 11, 598155.	1.6	17
31	Identification of an Immune Gene-Associated Prognostic Signature and Its Association With a Poor Prognosis in Gastric Cancer Patients. Frontiers in Oncology, 2020, 10, 629909.	1.3	16
32	A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes and Diseases, 2019, 6, 419-430.	1.5	33
33	Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. Cell Communication and Signaling, 2019, 17, 121.	2.7	68
34	MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Letters, 2019, 459, 156-167.	3.2	36
35	STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. Journal of Experimental and Clinical Cancer Research, 2019, 38, 195.	3.5	249
36	Is CDK9 a promising target for both primary and metastatic osteosarcoma?. EBioMedicine, 2019, 40, 27-28.	2.7	4

#	Article	IF	Citations
37	Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Research, 2018, 78, 5656-5667.	0.4	42
38	Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes and Diseases, 2018, 5, 204-219.	1.5	66
39	Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis, 2018, 39, 1026-1036.	1.3	27
40	Inhibiting Î²-Catenin by Î²-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Frontiers in Pharmacology, 2018, 9, 5.	1.6	21
41	Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. Acta Biomaterialia, 2017, 58, 386-398.	4.1	37
42	Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Frontiers in Pharmacology, 2017, 8, 917.	1.6	28
43	Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1â€“MDM2â€“p53 Pathway. Progress in Molecular Biology and Translational Science, 2017, 151, 195-216.	0.9	20
44	Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. Journal of Controlled Release, 2016, 237, 101-114.	4.8	31
45	Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget, 2016, 7, 32566-32578.	0.8	27
46	Identification of linearifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. Journal of Biomedical Research, 2016, 30, 322-33.	0.7	23
47	Development and validation of a rapid HPLC method for quantitation of SPâ€141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography, 2015, 29, 654-663.	0.8	12
48	Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Medicinal Research Reviews, 2015, 35, 1220-1267.	5.0	93
49	RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Letters, 2015, 369, 386-395.	3.2	26
50	Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chinese Journal of Natural Medicines, 2015, 13, 554-560.	0.7	2
51	Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation. Oncotarget, 2015, 6, 2623-2640.	0.8	55
52	Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization,in vitroandin vivoanti-prostate cancer activity, and mechanisms of action. Oncotarget, 2015, 6, 21379-21394.	0.8	57
53	Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget, 2015, 6, 33106-33119.	0.8	28
54	The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications, 2014, 5, 5086.	5.8	70

#	Article	IF	Citations
55	Inulasesquiterpenoids: structural diversity, cytotoxicity and anti-tumor activity. Expert Opinion on Investigational Drugs, 2014, 23, 317-345.	1.9	100
56	A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 969, 235-240.	1.2	6
57	Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology, 2014, 147, 893-902.e2.	0.6	69
58	NFAT as cancer target: Mission possible?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 297-311.	3.3	90
59	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo. Oncotarget, 2014, 5, 11604-11619.	0.8	46
60	Chemical constiuents of Euonymus acanthocarpus. Chemistry of Natural Compounds, 2013, 49, 383-387.	0.2	6
61	Chemical Constituents from Aphanamixis grandifolia. Chemistry of Natural Compounds, 2013, 49, 486-492.	0.2	24
62	Identification and structural characterization of dimeric sesquiterpene lactones in Inula japonica Thunb. by highâ€performance liquid chromatography/electrospray ionization with multiâ€stage mass spectrometry. Rapid Communications in Mass Spectrometry, 2013, 27, 2159-2169.	0.7	9
63	Bioactive eudesmane and germacrane derivatives from Inula wissmanniana Hand.-Mazz.. Phytochemistry, 2013, 96, 214-222.	1.4	24
64	Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz.. European Journal of Medicinal Chemistry, 2013, 68, 473-481.	2.6	41
65	Aphanamgrandiol A, a new triterpenoid with a unique carbon skeleton from Aphanamixis grandifolia. FÃ¬toterapÃ¬Â¢, 2013, 86, 217-221.	1.1	11
66	Hookerolides Aâ€“D, the first naturally occurring C17-pseudoguaianolides from Inula hookeri. Tetrahedron Letters, 2013, 54, 1943-1946.	0.7	12
67	miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents. Current Cancer Drug Targets, 2013, 13, 519-541.	0.8	33
68	Identification of the ZAK-MKK4-JNK-TGFβ Signaling Pathway as a Molecular Target for Novel Synthetic Iminoquinone Anticancer Compound BA-TPQ. Current Cancer Drug Targets, 2013, 13, 651-660.	0.8	8
69	Sesquiterpenoids fromInula racemosaHook. f. Inhibit Nitric Oxide Production. Planta Medica, 2012, 78, 166-171.	0.7	27
70	Sesquiterpene Lactones from Inula hupehensis Inhibit Nitric Oxide Production in RAW264.7 Macrophages. Planta Medica, 2012, 78, 1002-1009.	0.7	25
71	Lineariifolianoids Aâ€“D, rare unsymmetrical sesquiterpenoid dimers comprised of xanthane and guaiane framework units from Inula lineariifolia. RSC Advances, 2012, 2, 1307.	1.7	28
72	Argutalactone, an unprecedented sesquiterpenoid lactone with a 6/5/7 tricyclic system fromIncarvillea arguta. Journal of Asian Natural Products Research, 2012, 14, 496-502.	0.7	3

#	Article	IF	Citations
73	Norlignans and Phenylpropanoids from Metasequoia glyptostroboidesHu et Cheng. Helvetica Chimica Acta, 2012, 95, 606-612.	1.0	6
74	Chemical Constituents of Plants from the Genus Euonymus. Chemistry and Biodiversity, 2012, 9, 1055-1076.	1.0	18
75	Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemotherapy and Pharmacology, 2012, 69, 1423-1431.	1.1	9
76	Terpenoids from Inula sericophylla Franch. and their chemotaxonomic significance. Biochemical Systematics and Ecology, 2012, 42, 75-78.	0.6	13
77	2,3-Seco- and 3,4-seco-tirucallane triterpenoid derivatives from the stems of Aphanamixis grandifolia Blume. Phytochemistry, 2012, 80, 148-155.	1.4	22
78	JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-Regulation of p21. PLoS ONE, 2012, 7, e34303.	1.1	32
79	Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2. PLoS ONE, 2012, 7, e41586.	1.1	73
80	Ginsenosides as anticancer agents: In vitro and in vivo activities, structureâ€“activity relationships, and molecular mechanisms of action. Frontiers in Pharmacology, 2012, 3, 25.	1.6	272
81	Pseudoguaianolides and Guaianolides from Inula hupehensis as Potential Anti-inflammatory Agents. Journal of Natural Products, 2011, 74, 1881-1887.	1.5	52
82	Chemical constituents of the aerial parts of Aconitum kongboense. Chemistry of Natural Compounds, 2011, 47, 854-855.	0.2	2
83	Three New Neolignans and One New Phenylpropanoid from the Leaves and Stems of Toona ciliata var. pubescens. Helvetica Chimica Acta, 2011, 94, 1685-1691.	1.0	7
84	Chemical Constituents of Plants from the Genus Geum. Chemistry and Biodiversity, 2011, 8, 203-222.	1.0	20
85	Four New Sesquiterpenoids from the Roots of Incarvillea arguta and Their Inhibitory Activities against Lipopolysaccharide-Induced Nitric Oxide Production. Chemical and Pharmaceutical Bulletin, 2010, 58, 1263-1266.	0.6	17
86	Three New Phenylpropanoids from Inula nervosa<scp>Wall</scp>.. Helvetica Chimica Acta, 2010, 93, 1418-1421.	1.0	16
87	Chemical Constituents of Plants from the Genus Dracocephalum. Chemistry and Biodiversity, 2010, 7, 1911-1929.	1.0	65
88	New sesquiterpenes from Inula japonica Thunb. with their inhibitory activities against LPS-induced NO production in RAW264.7 macrophages. Tetrahedron, 2010, 66, 9379-9388.	1.0	69
89	Sesquiterpenoids from Inula linearifolia Inhibit Nitric Oxide Production. Journal of Natural Products, 2010, 73, 1117-1120.	1.5	58
90	Two New Cytotoxic Biphenyls from the Roots ofIncarvillea arguta. Helvetica Chimica Acta, 2009, 92, 491-494.	1.0	12

#	Article	IF	Citations
91	Chemical Constituents of Plants from the Genus Incarvillea. Chemistry and Biodiversity, 2009, 6, 818-826.	1.0	13
92	Ainsliatrimers A and B, the First Two Guaianolide Trimers from Ainsliaea fulvioides. Organic Letters, 2008, 10, 5517-5520.	2.4	62
93	Indole Diketopiperazine Alkaloids Isolated From the Marine-Derived Fungus Aspergillus chevalieri MCCC M23426. Frontiers in Microbiology, 0, 13, .	1.5	5